Market Cap 13.88M
Revenue (ttm) 710,000.00
Net Income (ttm) -11.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,676.06%
Debt to Equity Ratio 0.00
Volume 49,000
Avg Vol 117,224
Day's Range N/A - N/A
Shares Out 24.79M
Stochastic %K 38%
Beta 0.34
Analysts Strong Sell
Price Target $3.75

Company Profile

Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. Its DehydraTECH is...

Industry: Biotechnology
Sector: Healthcare
Phone: 250 765 6424
Address:
740 McCurdy Road, Suite 100, Kelowna, Canada
paolo73
paolo73 Jul. 3 at 6:35 AM
$LEXX Let's write to the company—I keep doing it, but one person alone can't achieve anything; if enough of us do it, they have to respond. Or we could write on their LinkedIn page, under their posts... We need to make our voices heard somehow, and they are accountable to the shareholders. There's no point in just complaining here; it doesn't accomplish anything.
0 · Reply
hovian
hovian Jul. 2 at 5:14 PM
$LEXX cant make 60 plus? oh boy... these company trade stock... make me sad... cant go up... come on is time...
0 · Reply
Tony7873
Tony7873 Jul. 2 at 5:09 PM
$LEXX 🤣😢😂🫣😭🤮🤑
0 · Reply
The_Wealth_Maker
The_Wealth_Maker Jul. 1 at 11:01 PM
$LEXX 😎
0 · Reply
Makingmillions192
Makingmillions192 Jun. 30 at 7:54 PM
$LEXX It’s really clockwork here 😂 technicals start flipping bullish and every short retard in the land rears their head.
1 · Reply
Makingmillions192
Makingmillions192 Jun. 30 at 7:52 PM
$LEXX The price is where it is because you are investing in a pre-revenue Biotech stock. And it’s the perfect environment for rtards like you guys showing up to short a company and pretend like your genius’s in your fairy dresses. Must be getting upset that your short position is gaining anymore ground eh? Going to feel really good in that arse of yours soon tiny taco and palo falto
0 · Reply
paolo73
paolo73 Jun. 30 at 6:18 PM
$LEXX This CEO is incompetent and the whole team, they don't care about the shareholders, I read the annual letter to the shareholders, they should be fed it.... they take a lot of money, a lot of words but zero facts.... that's why the price is this because there are no facts, they even compliment the companies whose drugs are approved but can you be so stupid.... I'm really pissed off with these 7 incompetents paid their weight in gold
0 · Reply
paolo73
paolo73 Jun. 30 at 3:48 PM
$LEXX Excuse me, when does the six-month extension for the *dommaro* expire? Thanks.
0 · Reply
Makingmillions192
Makingmillions192 Jun. 30 at 3:11 PM
$LEXX Coiled spring 🚀 👀
0 · Reply
Makingmillions192
Makingmillions192 Jun. 30 at 3:11 PM
$LEXX If Human Study #7 delivers the expected uniform, steady-state blood absorption graphs, Lexaria's valuation framework completely detaches from its current $13.5M floor. Here is how the numbers shake out based on industry comps: Bear Case: $1.00 to $1.50 per share (~$30M Market Cap). The baseline tech is proven, establishing a solid cash-and-IP liquidation floor that doubles the current tape. Base Case: $3.50 to $4.50 per share (~$100M Market Cap). Direct alignment with independent analyst consensus. Successful human tablet data completely de-risks the platform, forcing the current "PharmaCO" MTA partner to commit to an upfront licensing structure to lock out competing suitors. Blue Sky Case: $6.00+ per share ($150M+ Market Cap). Study #7 explicitly outperforms commercial Wegovy tablets on side effects and absorption. A massive, multi-bidder out-licensing war ignites between generic manufacturers and Big Pharma giants, mimicking Emisphere’s historical validation arc.
0 · Reply
Latest News on LEXX
Lexaria Bioscience begins dosing in animal study GLP-1-A26-1

2026-06-23T15:26:36.000Z - 11 days ago

Lexaria Bioscience begins dosing in animal study GLP-1-A26-1


Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule

Jun 23, 2026, 9:25 AM EDT - 11 days ago

Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule


Lexaria's Animal Study GLP-1-A26-1 has Begun Dosing on Schedule

Jun 23, 2026, 9:25 AM EDT - 11 days ago

Lexaria's Animal Study GLP-1-A26-1 has Begun Dosing on Schedule


Lexaria Bioscience provides update on GLP-1 oral pill market

2026-06-17T13:42:22.000Z - 17 days ago

Lexaria Bioscience provides update on GLP-1 oral pill market


Lexaria announces dosing completion in 2026 Animal Study 2

2026-06-09T13:34:05.000Z - 25 days ago

Lexaria announces dosing completion in 2026 Animal Study 2


Lexaria Bioscience Slides: Corporate presentation

May 27, 2026, 7:00 AM EDT - 5 weeks ago

Lexaria Bioscience Slides: Corporate presentation


Lexaria Bioscience provides update on Human Pilot Study #7

2026-05-05T13:24:25.000Z - 2 months ago

Lexaria Bioscience provides update on Human Pilot Study #7

NVO


Lexaria Updates Progress on Human Study #7

May 5, 2026, 9:10 AM EDT - 2 months ago

Lexaria Updates Progress on Human Study #7


Lexaria Bioscience provides update on GLP-1 oral pill market

2026-04-21T15:02:42.000Z - 2 months ago

Lexaria Bioscience provides update on GLP-1 oral pill market


Lexaria Bioscience engages CRO for 2026 GLP-1-A26-1 study

2026-04-15T13:24:10.000Z - 2 months ago

Lexaria Bioscience engages CRO for 2026 GLP-1-A26-1 study


Lexaria Bioscience Quarterly report: Q2 2026

Apr 13, 2026, 8:00 AM EDT - 2 months ago

Lexaria Bioscience Quarterly report: Q2 2026


Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval

Apr 7, 2026, 9:10 AM EDT - 3 months ago

Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval


Lexaria Bioscience to begin new human clinical study in GLP-1

2026-04-01T13:26:48.000Z - 3 months ago

Lexaria Bioscience to begin new human clinical study in GLP-1


Lexaria to Begin New Human Clinical Study in GLP-1

Apr 1, 2026, 9:20 AM EDT - 3 months ago

Lexaria to Begin New Human Clinical Study in GLP-1


Lexaria's Robust Patent Portfolio Continues to Grow

Mar 26, 2026, 9:20 AM EDT - 3 months ago

Lexaria's Robust Patent Portfolio Continues to Grow


Lexaria's Oral GLP-1 Drug Strategy Validated by Industry

Mar 24, 2026, 9:15 AM EDT - 3 months ago

Lexaria's Oral GLP-1 Drug Strategy Validated by Industry


Lexaria Bioscience announces 2026 R&D plans

2026-03-04T14:39:22.000Z - 4 months ago

Lexaria Bioscience announces 2026 R&D plans


Lexaria Announces New R&D Plans for 2026

Mar 4, 2026, 9:25 AM EST - 4 months ago

Lexaria Announces New R&D Plans for 2026


Lexaria announces final results from GLP-1-H25-5 study

2026-02-05T14:25:56.000Z - 5 months ago

Lexaria announces final results from GLP-1-H25-5 study


Lexaria Bioscience awarded six additional patents

2026-01-22T14:25:16.000Z - 5 months ago

Lexaria Bioscience awarded six additional patents


Lexaria Awarded Six Additional Patents

Jan 22, 2026, 9:20 AM EST - 5 months ago

Lexaria Awarded Six Additional Patents


Lexaria Bioscience Quarterly report: Q1 2026

Jan 13, 2026, 7:00 AM EST - 6 months ago

Lexaria Bioscience Quarterly report: Q1 2026


Lexaria Releases Annual Letter from the CEO

Jan 12, 2026, 9:10 AM EST - 6 months ago

Lexaria Releases Annual Letter from the CEO


Lexaria Bioscience Registration statement: Registration filing

Dec 29, 2025, 7:00 AM EST - 6 months ago

Lexaria Bioscience Registration statement: Registration filing


Lexaria Bioscience Proxy statement: Proxy filing

Dec 10, 2025, 7:00 AM EST - 7 months ago

Lexaria Bioscience Proxy statement: Proxy filing


Lexaria Bioscience Registration statement: Registration filing

Dec 5, 2025, 7:00 AM EST - 7 months ago

Lexaria Bioscience Registration statement: Registration filing


Lexaria Bioscience Annual report: Q4 2025

Nov 28, 2025, 7:00 AM EST - 7 months ago

Lexaria Bioscience Annual report: Q4 2025


Lexaria Bioscience Registration statement: Registration filing

Oct 14, 2025, 8:00 AM EDT - 9 months ago

Lexaria Bioscience Registration statement: Registration filing


Lexaria Bioscience Corp. Provides Strategic Update

Oct 9, 2025, 9:20 AM EDT - 9 months ago

Lexaria Bioscience Corp. Provides Strategic Update


GLP-1 "Arms Race" Broadens to Include Dozens of Companies

Aug 6, 2025, 9:20 AM EDT - 11 months ago

GLP-1 "Arms Race" Broadens to Include Dozens of Companies


Lexaria Bioscience Quarterly report: Q3 2025

Jul 14, 2025, 8:00 AM EDT - 1 year ago

Lexaria Bioscience Quarterly report: Q3 2025


Lexaria Bioscience Quarterly report: Q2 2025

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Lexaria Bioscience Quarterly report: Q2 2025


Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Apr 3, 2025, 9:10 AM EDT - 1 year ago

Lexaria Updates its Ongoing Human Study GLP-1-H24-4


Lexaria's Human GLP-1 Study #5 Begins Dosing

Apr 2, 2025, 9:05 AM EDT - 1 year ago

Lexaria's Human GLP-1 Study #5 Begins Dosing


paolo73
paolo73 Jul. 3 at 6:35 AM
$LEXX Let's write to the company—I keep doing it, but one person alone can't achieve anything; if enough of us do it, they have to respond. Or we could write on their LinkedIn page, under their posts... We need to make our voices heard somehow, and they are accountable to the shareholders. There's no point in just complaining here; it doesn't accomplish anything.
0 · Reply
hovian
hovian Jul. 2 at 5:14 PM
$LEXX cant make 60 plus? oh boy... these company trade stock... make me sad... cant go up... come on is time...
0 · Reply
Tony7873
Tony7873 Jul. 2 at 5:09 PM
$LEXX 🤣😢😂🫣😭🤮🤑
0 · Reply
The_Wealth_Maker
The_Wealth_Maker Jul. 1 at 11:01 PM
$LEXX 😎
0 · Reply
Makingmillions192
Makingmillions192 Jun. 30 at 7:54 PM
$LEXX It’s really clockwork here 😂 technicals start flipping bullish and every short retard in the land rears their head.
1 · Reply
Makingmillions192
Makingmillions192 Jun. 30 at 7:52 PM
$LEXX The price is where it is because you are investing in a pre-revenue Biotech stock. And it’s the perfect environment for rtards like you guys showing up to short a company and pretend like your genius’s in your fairy dresses. Must be getting upset that your short position is gaining anymore ground eh? Going to feel really good in that arse of yours soon tiny taco and palo falto
0 · Reply
paolo73
paolo73 Jun. 30 at 6:18 PM
$LEXX This CEO is incompetent and the whole team, they don't care about the shareholders, I read the annual letter to the shareholders, they should be fed it.... they take a lot of money, a lot of words but zero facts.... that's why the price is this because there are no facts, they even compliment the companies whose drugs are approved but can you be so stupid.... I'm really pissed off with these 7 incompetents paid their weight in gold
0 · Reply
paolo73
paolo73 Jun. 30 at 3:48 PM
$LEXX Excuse me, when does the six-month extension for the *dommaro* expire? Thanks.
0 · Reply
Makingmillions192
Makingmillions192 Jun. 30 at 3:11 PM
$LEXX Coiled spring 🚀 👀
0 · Reply
Makingmillions192
Makingmillions192 Jun. 30 at 3:11 PM
$LEXX If Human Study #7 delivers the expected uniform, steady-state blood absorption graphs, Lexaria's valuation framework completely detaches from its current $13.5M floor. Here is how the numbers shake out based on industry comps: Bear Case: $1.00 to $1.50 per share (~$30M Market Cap). The baseline tech is proven, establishing a solid cash-and-IP liquidation floor that doubles the current tape. Base Case: $3.50 to $4.50 per share (~$100M Market Cap). Direct alignment with independent analyst consensus. Successful human tablet data completely de-risks the platform, forcing the current "PharmaCO" MTA partner to commit to an upfront licensing structure to lock out competing suitors. Blue Sky Case: $6.00+ per share ($150M+ Market Cap). Study #7 explicitly outperforms commercial Wegovy tablets on side effects and absorption. A massive, multi-bidder out-licensing war ignites between generic manufacturers and Big Pharma giants, mimicking Emisphere’s historical validation arc.
0 · Reply
Makingmillions192
Makingmillions192 Jun. 30 at 2:27 PM
$LEXX Shorts look like they are out of ammo. Human study 7 could drop as early as mid August… that’s the golden ticket 💰 Short cover and melt from here to there 📈
0 · Reply
Makingmillions192
Makingmillions192 Jun. 30 at 1:26 PM
$LEXX DehydraTECH is highly likely to perform more effectively in a tablet than a capsule because the format perfectly aligns with the physics of gastric absorption. Oral semaglutide requires a highly localized environment to absorb through the stomach wall before washing into the less efficient intestinal tract. While Lexaria’s past capsule trials showed great results, capsules dissolve rapidly and disperse their contents throughout the entire gastric fluid, leading to erratic delivery. By engineering DehydraTECH into a dense tablet for Human Study #7, Lexaria mimics Novo Nordisk’s stomach-adherence mechanics. The tablet sits directly against the stomach lining, creating a highlyconcentrated zone that optimizes absorption. This should maximize overall bioavailability while flattening the wild patient-to-patient blood variability that plagues current oral GLP-1s. $LLY $NVO $PFE
0 · Reply
Makingmillions192
Makingmillions192 Jun. 30 at 1:07 PM
$LEXX Feeling pretty confident we are sitting on a 10x from here to Sept/Oct
0 · Reply
Makingmillions192
Makingmillions192 Jun. 30 at 1:05 PM
$LEXX If Human Study #7 hits a home run—proving that DehydraTECH works in a standard tablet format at a 5-week steady state with lower GI side effects—Rich has exactly what he needs to ink a deal. The remaining animal studies (Animal Study #2 for next-gen retatrutide/amycretin, and the 11-arm Non-SNAC study) act as leverage to drive the price up while the primary deal is being hammered out. The price will catapulted on study #7 if it’s successful because the market knows that is the golden ticket 💰 Expecting a melt-up from here to there. $LLY $NVO
0 · Reply
Taco_stocks
Taco_stocks Jun. 30 at 12:11 AM
$LEXX Why are you guys still listening to MM? He has been wrong about *literally* every single LEXX prediction he made.
0 · Reply
hovian
hovian Jun. 29 at 7:48 PM
$LEXX anyone saw where the volume went?...is missing for a few days now...hope we gonna see him back!
0 · Reply
hovian
hovian Jun. 29 at 7:18 PM
$LEXX from now on SP will slowly hike imho... sweet will b.
1 · Reply
Makingmillions192
Makingmillions192 Jun. 29 at 7:09 PM
$LEXX Moving Lexaria’s DehydraTECH to a 5-week steady-state tablet format tackles Big Pharma’s biggest hurdles: erratic absorption and terrible side effects. Commercial oral GLP-1 tablets work by adhering to the stomach lining. By matching this form factor, DehydraTECH should flatten wild patient-to-patient blood variations and deliver highly uniform bioavailability. Furthermore, past data shows Lexaria cuts gastrointestinal side effects by up to 50%. Over 5 weeks, avoiding sharp daily drug spikes will prove DehydraTECH offers superior long-term tolerability. If the data confirms a smooth, highly uniform steady-state blood graph in a plug-and-play tablet format, it removes the final manufacturing risks keeping Big Pharma licensing dollars on the sidelines. Should continue to rally now until data readout Aug/September and potential the most exciting period for this company in its history. $LLY $NVO $PFE $SUNPHARMA.NSE
0 · Reply
Makingmillions192
Makingmillions192 Jun. 29 at 6:53 PM
$LEXX The main event is late July to Early August 2026: Final steady-state data drops for Human Pilot Study #7 (GLP-1-H26-7). Dosing began June 14th and wraps up its 5-week schedule on July 19th. If you look at this strictly from the perspective of what a multi-billion dollar M&A or business development board cares about, Human Pilot Study #7 (the head-to-head vs. commercial Wegovy tablets) is the absolute holy grail. So we could see early signs of MTA action as early as August. While the animal studies are great for expanding the future pipeline, Study #7 is the exact gatekeeper for Lexaria's immediate valuation and the ultimate catalyst for a Big Pharma deal. The other two studies are expected as follows: Mid-to-Late Summer 2026: Unblinded pharmacokinetic (PK) results for Animal Study #2 (GLP-1-A26-2). Early September 2026: Final unblinded readouts for the massive 11-arm Animal Study (GLP-1-A26-1). Pointing to a very exciting fall.
0 · Reply
Makingmillions192
Makingmillions192 Jun. 29 at 5:53 PM
$LEXX The market will churn until datasets come out July, August, and September, and then if data hits, we could go into a licensing bidding war. If we strike a $10–20M upfront payment with $100M+ in potential backend milestones and tiered royalties, then the re-rate could be a massive jump from our current $13.5M market cap straight to a $100M+ valuation, launching the share price from $0.54 into a stable $4.00 to $6.00 range overnight. Warrants cash in, treasury is full, short thesis evaporates, RS off the table. First data set is due out in the next 20 trading…
0 · Reply
Makingmillions192
Makingmillions192 Jun. 29 at 5:09 PM
$LEXX Yes probably
0 · Reply
Makingmillions192
Makingmillions192 Jun. 29 at 5:06 PM
$LEXX Come on fuckers give me my 55s 😂
0 · Reply